Straumann takes over distribution of botiss products in Germany

  • Group strengthens position in European dental biomaterials market
     
  • botiss sales team in Germany transfers to Straumann
     
  • Agreement reflects strong partnership between the two companies

Basel, 18 July 2016 –Straumann and botiss biomaterials announced today that Straumann will take over the exclusive distribution of botiss products in Germany from the third quarter of 2016. At the same time, Straumann will take over the local sales team of the Berlin-based company, which until now has managed distribution in its domestic market directly.

 

The agreement further strengthens the partnership between the two companies, which aims at providing comprehensive solutions for oral tissue regeneration. The integration of botiss’ German distribution organization will also enhance Straumann’s position as a leading provider of dental biomaterials in Europe.

 

Wolfgang Becker, Head Sales Central Europe, explained: “The combination of our own products with botiss’ comprehensive line of regenerative solutions brings us closer to realizing our vision of being the total solution provider of choice in tooth replacement, in one of our major markets. Uniting our sales teams will improve coordination and efficiency and will further enhance customer service, enabling our customers to source all biomaterials they need from a single provider.”

 

Oliver Bielenstein, Managing Partner of botiss biomaterials, added: “This step will allow us to focus more intensively on product development and researching innovative solutions. Straumann’s commercial strength will help us to gain further market share in the key German market and to add value for dentists and patients with our solutions.”

 

 

About the partnership

Straumann and botiss biomaterials have been working together as partners since 2014, when the Swiss company acquired the exclusive distribution rights for botiss products in various countries worldwide and co-distribution rights in Germany. Straumann has an option to acquire up to 30% of the shares in botiss biomaterials in 2017.

 

 

About botiss biomaterials

botiss biomaterials is one of the largest providers of oral tissue regeneration products used in implantology, oral surgery, oral and maxillofacial surgery and parodontology. Its range of clinically tested solutions for dental bone and soft tissue regeneration includes membranes for guided tissue and bone regeneration, a comprehensive range of bovine, allogenic and synthetic bone graft materials, as well as products for soft tissue reconstruction. botiss products are used in dental clinics in more than 100 countries worldwide and have been tried and tested in clinical practice for many years. The innovative and rapidly growing company is privately ownership and was founded in 2008 by Managing Partners Oliver Bielenstein and Dr Dražen Tadić.

 

 

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and biomaterials for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 3500 people worldwide and its products and services are available in more than 100 countries through its broad network of distribution subsidiaries and partners.